WuXi AppTec acquires preclinical CRO
WuXi AppTec has acquired Shanghai-based HD Biosciences (HDB), a biology-focused preclinical contract research organization (CRO).
HD Biosciences, which also has facilities in Beijing and the US, will become a wholly-owned subsidiary of WuXi.
According to WuXi AppTec, the acquisition will strengthen the company’s research and development capabilities from target validation to lead discovery and optimization.
HD Biosciences’ capabilities include plate-based pharmacology and screening as well as AGMTM based target validation.
In a press statement, Dr. Xuehai Tan, Chairman and CEO of HD Biosciences, said the integration of services will enable the company to meet its growing customer needs.
